NCT04775784

Brief Summary

Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic disease caused by SARS-CoV-2 virus. Central Nervous System (CNS) complications associated with COVID-19 might be secondary sequelae due to exuberant systemic innate-mediated hyper-inflammation, which may impair neurovascular endothelial function, disrupt blood brain barrier (BBB), activates CNS innate immune signaling pathways, and induces parainfectious autoimmunity, potentially contributing to the CNS manifestations. Although the predominant clinical manifestation of SARS-CoV-2 is characterized by dyspnea, unremitting fever and hypoxemic respiratory failure, neurologic manifestations do occur in most hospitalized SARS-CoV-2 patients and include non-specific encephalopathy, psychosis, meningitis/encephalitis, myelitis, cerebrovascular events, Guillain-Barre' syndrome, and cranial or peripheral neuropathies, such as anosmia and ageusia. To date, data about primary CNS involvement due to neurotropism and direct neuroinvasion are still lacking.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 17, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 25, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 1, 2021

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

April 18, 2023

Status Verified

April 1, 2023

Enrollment Period

1.5 years

First QC Date

February 25, 2021

Last Update Submit

April 14, 2023

Conditions

COVID-19 TestingCNS DiseaseCNS Infection

Keywords

SARS-Cov-2CNS infectionCoronavirusBrain

Outcome Measures

Primary Outcomes (1)

  • Determination of SARS-CoV-2 presence in the CNS

    Brain tissue sampling analysis

    Surgery

Study Arms (1)

Adult neurosurgical patients

Adult, both sex, neurosurgical patients candidate for intracranial surgery, able to sign informed consent.

Diagnostic Test: Determination of SARS-CoV2 presence in CNS

Interventions

Determination of SARS-CoV2 presence in CNSDIAGNOSTIC_TEST

Brain tissue sampling

Adult neurosurgical patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients eligible to CNS surgery

You may qualify if:

  • Adult patients
  • Patients candidate for CNS surgery
  • Patients who have been tested for nasopharyngeal swab for SARS-CoV-2
  • Patients who have been tested for serology test for anti SARS-CoV-2 immunoglobulinG (IgG) and immunoglobulinM (IgM) antibodies
  • Patients able to sign informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS San Raffaele Scientific Institute

Milan, 20132, Italy

RECRUITING

Related Publications (15)

  • Noorwali AA, Turkistani AM, Asiri SI, Trabulsi FA, Alwafi OM, Alzahrani SH, Rashid MM, Hegazy SA, Alzaydi MD, Bawakid KO. Descriptive epidemiology and characteristics of confirmed cases of Middle East respiratory syndrome coronavirus infection in the Makkah Region of Saudi Arabia, March to June 2014. Ann Saudi Med. 2015 May-Jun;35(3):203-9. doi: 10.5144/0256-4947.2015.203.

    PMID: 26409794BACKGROUND

  • Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg. 2020 Jul;194:105921. doi: 10.1016/j.clineuro.2020.105921. Epub 2020 May 15.

    PMID: 32422545BACKGROUND

  • Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, Koralnik IJ. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020 Nov;7(11):2221-2230. doi: 10.1002/acn3.51210. Epub 2020 Oct 5.

    PMID: 33016619BACKGROUND

  • Berger JR. COVID-19 and the nervous system. J Neurovirol. 2020 Apr;26(2):143-148. doi: 10.1007/s13365-020-00840-5. Epub 2020 May 23.

    PMID: 32447630BACKGROUND

  • Najjar S, Najjar A, Chong DJ, Pramanik BK, Kirsch C, Kuzniecky RI, Pacia SV, Azhar S. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020 Aug 6;17(1):231. doi: 10.1186/s12974-020-01896-0.

    PMID: 32758257BACKGROUND

  • Liu J, Xie W, Wang Y, Xiong Y, Chen S, Han J, Wu Q. A comparative overview of COVID-19, MERS and SARS: Review article. Int J Surg. 2020 Sep;81:1-8. doi: 10.1016/j.ijsu.2020.07.032. Epub 2020 Jul 26.

    PMID: 32730205BACKGROUND

  • Kumar A, Pareek V, Prasoon P, Faiq MA, Kumar P, Kumari C, Narayan RK. Possible routes of SARS-CoV-2 invasion in brain: In context of neurological symptoms in COVID-19 patients. J Neurosci Res. 2020 Dec;98(12):2376-2383. doi: 10.1002/jnr.24717. Epub 2020 Aug 31.

    PMID: 32869376BACKGROUND

  • Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, Lu P, Weizman OE, Liu F, Dai Y, Szigeti-Buck K, Yasumoto Y, Wang G, Castaldi C, Heltke J, Ng E, Wheeler J, Alfajaro MM, Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazmi SAJ, Zhang K, Wilen CB, Horvath TL, Plu I, Haik S, Thomas JL, Louvi A, Farhadian SF, Huttner A, Seilhean D, Renier N, Bilguvar K, Iwasaki A. Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv [Preprint]. 2020 Sep 8:2020.06.25.169946. doi: 10.1101/2020.06.25.169946.

    PMID: 32935108BACKGROUND

  • Virhammar J, Kumlien E, Fallmar D, Frithiof R, Jackmann S, Skold MK, Kadir M, Frick J, Lindeberg J, Olivero-Reinius H, Ryttlefors M, Cunningham JL, Wikstrom J, Grabowska A, Bondeson K, Bergquist J, Zetterberg H, Rostami E. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology. 2020 Sep 8;95(10):445-449. doi: 10.1212/WNL.0000000000010250. Epub 2020 Jun 25.

    PMID: 32586897BACKGROUND

  • Espindola OM, Brandao CO, Gomes YCP, Siqueira M, Soares CN, Lima MASD, Leite ACCB, Torezani G, Araujo AQC, Silva MTT. Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development. Int J Infect Dis. 2021 Jan;102:155-162. doi: 10.1016/j.ijid.2020.10.044. Epub 2020 Oct 28.

    PMID: 33127503BACKGROUND

  • Bernard-Valnet R, Pizzarotti B, Anichini A, Demars Y, Russo E, Schmidhauser M, Cerutti-Sola J, Rossetti AO, Du Pasquier R. Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. Eur J Neurol. 2020 Sep;27(9):e43-e44. doi: 10.1111/ene.14298. Epub 2020 May 30. No abstract available.

    PMID: 32383343BACKGROUND

  • Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020 Jul;92(7):699-702. doi: 10.1002/jmv.25915.

    PMID: 32314810BACKGROUND

  • Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JL, Padera RF Jr, Sabeti P. Neuropathological Features of Covid-19. N Engl J Med. 2020 Sep 3;383(10):989-992. doi: 10.1056/NEJMc2019373. Epub 2020 Jun 12. No abstract available.

    PMID: 32530583BACKGROUND

  • Pereira A. Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic. Front Neurol. 2020 Apr 17;11:308. doi: 10.3389/fneur.2020.00308. eCollection 2020. No abstract available.

    PMID: 32362868BACKGROUND

  • Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020 Oct;41(10):2657-2669. doi: 10.1007/s10072-020-04575-3. Epub 2020 Jul 28.

    PMID: 32725449BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Brain tissue samples

MeSH Terms

Conditions

Central Nervous System DiseasesCentral Nervous System InfectionsCoronavirus Infections

Condition Hierarchy (Ancestors)

Nervous System DiseasesInfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsVirus Diseases

Study Officials

  • Pietro Mortini, MD, Prof.

    IRCCS San Raffaele Scientific Institute

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Laura Sincinelli

CONTACT

00390226435568sincinelli.laura@hsr.it

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 25, 2021

First Posted

March 1, 2021

Study Start

December 17, 2020

Primary Completion

June 1, 2022

Study Completion

December 31, 2023

Last Updated

April 18, 2023

Record last verified: 2023-04

Locations

IT(1)